Short answer
Insulet Corporation (PODD) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $842M (up 19.2% year over year) with net income of $141M.
Q3 2026 key financials · XBRL
- Revenue
- $842M
- +19.2% YoY · +5.0% QoQ
- Net income
- $141M
- +61.0% YoY · +48.4% QoQ
- Operating margin
- 22.5%
- Gross margin
- 75.1%
- EPS (diluted)
- $2.02
- +64.2% YoY · +47.4% QoQ
Source: XBRL data from the Insulet Corporation (PODD) Q3 2026 10-Q on SEC EDGAR. USD.
Insulet Corporation Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $842.0M, up 19.2% YoY from $706.3M, driven by Omnipod Products growth
- Gross margin 75.1% vs 72.2% YoY, benefiting from manufacturing efficiencies and warranty accrual adjustment
- International Omnipod revenue $266.2M, up 31.7%; Drug Delivery $5.5M, down 22.7%
- Operating cash flow $325.7M, down from $386.0M; capital expenditures $113.9M and share repurchases $300.0M
- 2026 capital expenditures expected to increase; tariff exemption removal could materially pressure future gross margin
Risk Factors
- No material changes to risks disclosed in the December 31, 2025 Form 10-K
- Carried-forward risks include business, financial condition, results of operations, and cash flows exposures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Insulet Corporation quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.